首页|期刊导航|世界中医药|丁二磺酸腺苷蛋氨酸联合肝爽颗粒治疗酒精性肝病临床效果

丁二磺酸腺苷蛋氨酸联合肝爽颗粒治疗酒精性肝病临床效果OA北大核心CHSSCDCSTPCD

Clinical Efficacy of Ademetionine 1,4-butanedisulfonate Combined with Ganshuang Granules Against Alcoholic Liver Disease

中文摘要英文摘要

目的:观察腺苷蛋氨酸联合肝爽颗粒治疗酒精性肝病患者的临床疗效及对肝纤维化指标的影响.方法:选取2019年7月至2021年6月陕西中医药大学附属医院肝病医院收治的110例酒精性肝病患者作为研究对象,按照随机数字表法随机分为观察组和对照组,每组55例.对照组给予酒精性肝病基础疗法结合肝爽颗粒治疗,肝爽颗粒温开水冲服,1袋/次,3次/d.观察组给予丁二磺酸腺苷蛋氨酸联合肝爽颗粒治疗,肝爽颗粒服用方案同对照组,同时注射丁二磺酸腺苷蛋氨酸1.0 g+250 mL0.9%氯化钠注射液缓慢静脉滴注,1次/d.2组均1个月为1个疗程,治疗3个疗程.分别于治疗前后检测肝功指标[直接胆红素(DBIL)、谷氨酰转移酶(GGT)、胆汁酸(BA)]、肝纤维化指标[脯氨酸肽酶(PLD)、Ⅳ型胶原(Ⅳ-C)、Ⅰ型前胶原氨端肽原(PINP)]、炎症介质[干扰素诱导蛋白-10(IP-10)、C-X-C基序趋化因子配体1(CXCL1)、可溶性血管细胞黏附分子-1(VCAM-1)],记录2组患者治疗期间发生的不良反应,计算总有效率.结果:治疗后,2组患者DBIL、GGT、BA水平均较治疗前降低,且观察组DBIL、GGT、BA水平均低于对照组,差异有统计学意义(P<0.05);治疗后,2组患者PLD、Ⅳ-C、PINP水平均较治疗前降低,且观察组PLD、Ⅳ-C、PINP水平均低于对照组,差异有统计学意义(P<0.05).治疗后,2组患者IP-10、CXCL1、VCAM-1水平均较治疗前降低,且观察组I P-10、CXCL1、VCAM-1水平均低于对照组,差异有统计学意义(P<0.05).治疗期间观察组、对照组患者不良反应发生率分别为12.73%(7/55)、9.09%(5/55),差异无统计学意义(P>0.05).观察组、对照组总有效率分别为90.91%(50/55)、74.55%(41/55),观察组总有效率高于对照组,差异有统计学意义(P>0.05)o结论:丁二磺酸腺苷蛋氨酸联合肝爽颗粒治疗酒精性肝病效果显著,可改善肝功能及肝纤维化状态,降低炎症介质水平,治疗安全性较高.

Objective:To observe the clinical efficacy of ademetionine 1,4-butanedisulfonate combined with Ganshuang Granules in the treatment of patients with alcoholic liver disease and its effect on liver fibrosis markers.Methods:A total of 110 patients with alcoholic liver disease treated at the Hepatology Department of Affiliated Hospital of Shaanxi University of Chinese Medicine from July 2019 to June 2021 were enrolled and randomly divided into an observation group and a control group according to a random number table,with 55 patients in each group.The control group received basic therapy for alcoholic liver disease combined with Ganshuang Granules,which were taken with warm water,1 bag per dose,three times a day.The observation group received ademe-tionine 1,4-butanedisulfonate combined with Ganshuang Granules,with the same administration protocol of Ganshuang Granules as the control group,and an additional intravenous infusion of 1.0 g of ademetionine 1,4-butanedisulfonate and 250 mL of 0.9%sodi-um chloride injection,once daily.Both groups were treated for three courses,each course lasting one month.Liver function indica-tors[direct bilirubin(DBIL),gamma-glutamyl transferase(GGT),bile acid(BA)],liver fibrosis indicators[proline dipeptidase(PLD),type Ⅳ collagen(Ⅳ-C),procollagen type Ⅰ N-terminal peptide(PINP)],and inflammatory factors[interferon-induced protein-10(IP-10),C-X-C motif chemokine ligand 1(CXCL1),soluble vascular cell adhesion molecule-1(VCAM-1)]were meas-ured before and after treatment.Adverse reactions of the two groups during treatment were recorded,and the total effective rate was calculated.Results:After treatment,the levels of DBIL,GGT,and BA in both groups were lower than those before treatment,and the levels in the observation group were significantly lower than those in the control group(P<0.05).The levels of PLD,Ⅳ-C,and PINP in both groups after treatment were also reduced compared to those before treatment,and the levels in the observation group were significantly lower than those in the control group(P<0.05).Similarly,the levels of IP-10,CXCL1,and VCAM-1 in both groups after treatment decreased compared to those before treatment,with the observation group showing significantly lower levels than the control group(P<0.05).The incidence of adverse reactions was 12.73%(7/55)in the observation group and 9.09%(5/55)in the control group,with no statistically significant difference(P>0.05).The total effective rate was 90.91%(50/55)in the observation group and 74.55%(41/55)in the control group,with the observation group showing a significantly higher total ef-fective rate(P<0.05).Conclusion:Ademetionine 1,4-butanedisulfonate combined with Ganshuang Granules is highly effective in treating alcoholic liver disease,which can improve liver function and fibrosis markers and reduce inflammatory factor levels,demon-strating high safety.

南然;席奇;宋春荣;宋粉莉;刘永刚

陕西中医药大学附属医院肝病医院,咸阳,712000

中医学

酒精性肝病肝爽颗粒丁二磺酸腺苷蛋氨酸肝功能肝纤维化炎症介质

Alcoholic liver diseaseGanshuang GranulesAdemetionine 1,4-butanedisulfonateLiver functionLiver fibrosisInflammatory factors

《世界中医药》 2024 (015)

2319-2322,2328 / 5

国家自然科学基金项目(81670572)——GSK-3β调控端粒抑制自噬性细胞死亡保护肝IRI的机制研究;陕西省中医管理局中医药科研课题(LCPT128);陕西中医药大学校级科研课题(2020XK02)——柔木丹颗粒治疗肝硬化门静脉高压症的临床疗效观察

10.3969/j.issn.1673-7202.2024.15.018

评论